Empowering mental health professionals with peer-reviewed psychiatric research and insights
Page 2
More JCP Articles
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in bipolar type I disorder.
Academic Highlights
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report
August 13, 2025
A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in schizophrenia.
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
August 11, 2025
Medical Expenditure Panel Survey data showed that over half of adults with schizophrenia report cognitive impairments, which were associated with higher healthcare costs and lower quality of life.
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to…
Original Research
Effects of Alcohol Use on Cognition in Individuals With Neurocognitive Disorders
August 6, 2025
In a memory clinic cohort of patients with neurocognitive disorders, alcohol related cognitive impairment resulted in specific deficits involving cognitive control during delayed recall task.
Original Research
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
July 30, 2025
The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
Original Research
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
July 30, 2025
Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
